Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety ...
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose ...
CNN1 年
Vistagen Therapeutics, Inc.
Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for ...